drug · small molecule
selinexor
Marketedupdated 6mo agoby $KPTI Karyopharm Therapeutics Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 29 investigational indications.
indications
investigational
DLBCL
targets
Exportin-1
all catalysts(7)
approval · 7
Jul 3, 2019
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Jun 22, 2020
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Dec 18, 2020
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Mar 28, 2022
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Jul 15, 2022
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Mar 10, 2025
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Sep 26, 2025
approval
$KPTI
XPOVIO (SELINEXOR) — FDA approval
selinexor
→
Trials studying selinexor
- phase3Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- phase2A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- phase2Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
- phase2Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
- phase1Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase2Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 22, 2027
217 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (66)
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035compositionUS 10519139
- Aug 14, 2035method-of-use (U-2855)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035method-of-use (U-3018)US 11746102
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035formulationUS 11753401
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Aug 14, 2035compositionUS 11807629
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 3, 2033compositionUS 8999996
- Jul 26, 2032method-of-use (U-3018)US 10544108
- Jul 26, 2032method-of-use (U-2584)US 10544108
- Jul 26, 2032method-of-use (U-3018)US 10544108
- Jul 26, 2032method-of-use (U-2584)US 10544108
- Jul 26, 2032method-of-use (U-3018)US 10544108
- Jul 26, 2032method-of-use (U-2584)US 10544108
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-2584)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-3018)US 11034660
- Jul 26, 2032method-of-use (U-2855)US 11787771
- Jul 26, 2032method-of-use (U-3018)US 11787771
- Jul 26, 2032method-of-use (U-2584)US 11787771
- Jul 26, 2032method-of-use (U-3018)US 11787771
- Jul 26, 2032method-of-use (U-2855)US 11787771
- Jul 26, 2032method-of-use (U-2855)US 11787771
- Jul 26, 2032method-of-use (U-2855)US 12291508
- Jul 26, 2032method-of-use (U-2855)US 12291508
- Jul 26, 2032method-of-use (U-2584)US 12291508
- Jul 26, 2032method-of-use (U-2584)US 12291508
- Jul 26, 2032method-of-use (U-3018)US 12291508
- Jul 26, 2032method-of-use (U-2584)US 12291508
- Jul 26, 2032method-of-use (U-3018)US 9079865
- Jul 26, 2032method-of-use (U-2855)US 9079865
- Jul 26, 2032method-of-use (U-3018)US 9079865
- Jul 26, 2032method-of-use (U-2584)US 9079865
- Jul 26, 2032method-of-use (U-2584)US 9079865
- Jul 26, 2032method-of-use (U-2855)US 9079865
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
- Jul 26, 2032compositionUS 9714226
FDA exclusivities (17)
- Dec 18, 2027ODE*ODE*1.1y
- Dec 18, 2027ODE*ODE*1.1y
- Dec 18, 2027ODE*ODE*1.1y
- Dec 18, 2027ODE-346Orphan Drug (7y)1.1y
- Dec 18, 2027ODE*ODE*1.1y
- Dec 18, 2027ODE*ODE*1.1y
- Jun 22, 2027ODE*ODE*217d
- Jun 22, 2027ODE-310Orphan Drug (7y)217d
- Jun 22, 2027ODE*ODE*217d
- Jun 22, 2027ODE*ODE*217d
- Jun 22, 2027ODE*ODE*217d
- Jul 3, 2026ODE-257Orphan Drug (7y)
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
- Jul 3, 2026ODE*ODE*
News(6)
- Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raftDebtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with A…biospace · 14d ago
- Karyopharm, deep in debt, to sell itself in bankruptcyThe parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.biopharma_dive · 14d ago
- Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned mergerIn an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…fiercebiotech · 15d ago
- Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bidGeron has discontinued a phase 3 trial of its Rytelo in JAK inhibitor-pretreated myelofibrosis after an independent data monitoring committee ruled that the study was unlikely to succeed, just as N…fiercebiotech · 19d ago
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 2mo ago
- Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancerKaryopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported that its latest trial, c…endpoints · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that